Response Pharmaceuticals takes a new approach to weight loss with an oral small molecule designed to inhibit a protein called iMTP to reduce uptake of fats and cholesterol. While this drug’s lead indication is addressing weight gain in patients taking antipsychotics, the company is also exploring other metabolic indications such as patients who need a post-GLP-1 therapy. The post Response Pharma’s Novel Pill for Weight Loss Shows Promise as Post-GLP-1 Maintenance Therapy appeared first on MedCity News.

View Entire Post